Autoimmune thrombocytopenic purpura during pegylated interferon α treatment for chronic hepatitis C.
We describe a 72-year-old woman with chronic hepatitis C and autoimmune thrombocytopenic purpura (AITP) during pegylated interferon (PEG-IFN) alpha. Immunoglobulin G and antinuclear antibody were 2,113 mg/dL and 1,280 at the start, respectively. A liver biopsy negated autoimmune hepatitis. After a 48-week combination therapy with ribavirin, PEG-IFN alpha-2a was administered. At the 30th month, the platelet count was decreased to 1.1 x 10(4)/microL. Bone marrow biopsy disclosed normocellular marrow compatible with AITP. The platelet-associated IgG (PAIgG) titer rose to 500 ng/10(7) cells. Corticosteroid therapy was successful, and the platelet count and PAIgG titer reverted to 6.4 x 10(4)/microL and 57.3 ng/10(7) cells, respectively.
Kim
Soo Ryang
SR
Department of Gastroenterology, Kobe Asahi Hospital, Kobe, Japan.
Imoto
Susumu
S
Kudo
Masatoshi
M
Nakajima
Taisuke
T
Ando
Kenji
K
Mita
Keiji
K
Fukuda
Katsumi
K
Hong
Hyun Soo
HS
Lee
Yeong Ho
YH
Nakashima
Keiichi
K
Shoji
Ikuo
I
Nagano-Fujii
Motoko
M
Hotta
Hak
H
Hayashi
Yoshitake
Y
D000368:Aged; D004337:Drug Carriers; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000008:administration & dosage* / Q000627:therapeutic use; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
D004337:Drug Carriers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a